Cargando…
Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy
Over 26 million people worldwide suffer from heart failure, a disease associated with a 1 year mortality rate of 22%. Half of these patients present heart failure with preserved ejection fraction (HFpEF), for which there is no available therapy to improve prognosis. HFpEF is strongly associated with...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019215/ https://www.ncbi.nlm.nih.gov/pubmed/31963368 http://dx.doi.org/10.3390/jcm9010241 |